This global push is transforming biotechnology and medicine, yielding tools that promise greater precision in diagnosis and treatment.
Amazonian Scorpion Venom's Power Against Breast Cancer
Researchers in Brazil have identified a molecule within the venom of the Amazonian scorpion species Brotheas amazonicus that demonstrates remarkable effectiveness against breast cancer cells.
Targeted Action: The compound, named BamazScplp1, was shown in laboratory tests to induce necrosis (cell death) in breast cancer cells at levels comparable to the widely used chemotherapy drug, paclitaxel.
The Research Team: Scientists from the University of São Paulo’s Ribeirão Preto School of Pharmaceutical Sciences (FCFRP-USP), in collaboration with the National Institute for Amazonian Research (INPA) and Amazonas State University (UEA), are leading the effort to turn this venom component into a biopharmaceutical tool.
Genetic Expression: The team plans to use genetic expression techniques to produce this molecule reliably on an industrial scale, a crucial step for therapeutic development.
Revolutionizing Tissue Repair with Snake Venom
The same research groups in Brazil are leveraging snake venom proteins to advance medical technologies:
Fibrin Sealant: The Center for the Study of Venoms and Venomous Animals (CEVAP) has patented a "biological glue" made from enzymes extracted from rattlesnake venom (like Bothrops neuwiedi pauloensis and Crotalus durissus terrificus) combined with an animal-derived cryoprecipitate.
Current Applications: This fibrin sealant, which mimics the body's natural clotting process, is currently undergoing Phase Three clinical trials for nerve repair, bone healing, and restoring movement after spinal cord injury.
Next-Generation Sealant: The researchers are working to create an improved sealant by combining a new, genetically-expressed serine protease (cholinein-1) with a growth factor (CdtVEGF), both originally derived from rattlesnake venom, to potentially enhance vessel formation and simplify large-scale production.
Precision Medicine: The Rise of Radiotheranostics
At the Cancer Theranostics Innovation Center (CancerThera) in São Paulo, researchers are pursuing radiotheranostics, a strategy that combines diagnosis and treatment in a single, targeted approach.
Dual Function: The method involves attaching specific molecules to radioisotopes. Depending on the isotope chosen (positron or gamma emitters), the tagged molecule can be used for imaging/diagnosis. Once a tumor is identified, a more intensely radiating isotope can be substituted to destroy the cancer cells locally.
Wide Application: The center is studying this technique for various cancers, including multiple myeloma, head and neck cancer, liver cancer, lung cancer, and in patients with thyroid cancer who are resistant to standard radioactive iodine treatment.
A Personalized Vaccine Using Hybrid Dendritic Cells
An experimental immunotherapy approach is being developed at the University of São Paulo (ICB-USP) to train the immune system to fight cancer.
The Challenge: Cancer often compromises the function of dendritic cells, which are vital components of the immune system.
The Solution: Scientists create a personalized vaccine by fusing healthy dendritic cells (from a donor) with cancer cells taken directly from the patient’s tumor. The immune system interprets this fusion as a "transplant" and reacts violently, generating a robust immune response specifically against the patient's tumor.
Promising Results: This strategy has shown positive results in studies involving melanoma, kidney cancer, and, more recently, glioblastoma patients, and is moving toward a Phase Three clinical study.
Enhancing Brain Cancer Prognosis with AI and MRI
In France, researchers are leveraging Artificial Intelligence (AI) to improve the diagnosis and treatment planning for glioblastoma, an aggressive form of brain cancer.
The Goal: The team developed an AI model that analyzes Magnetic Resonance Imaging (MRI) scans to predict a patient's survival and treatment outcome.
Predicting Outcomes: The model is trained to reliably indicate whether the patient has the MGMT promoter region methylation DNA modification—a key prognostic factor that influences chemotherapy effectiveness.
High Accuracy: The AI model, developed using aerospace-inspired techniques, has demonstrated 80% to 90% accuracy in predicting patient survival, providing a non-invasive alternative to traditional biopsies.
WNCTimes
source: Fundação de Amparo à Pesquisa do Estado de São Paulo. "Amazon scorpion venom shows stunning power against breast cancer." ScienceDaily. ScienceDaily, 18 November 2025. <www.sciencedaily.com/releases/2025/11/251117095658.htm>.